Deep research and expert guides on maintaining your visual health.
Palmitoylethanolamide (PEA) in Glaucoma: A Review of Clinical Evidence Glaucoma is an eye disease marked by optic nerve damage, often linked to high intraocular pressure (IOP). Standard glaucoma treatments focus on lowering IOP, but researchers are exploring neuroprotective supplements as add-ons. One promising compound is palmitoylethanolamide (PEA), a naturally occurring fatty acid amide with an...
PEA stands for palmitoylethanolamide, a short name used to refer to the same naturally occurring fatty molecule. Like its full name, PEA plays a role in controlling inflammation and moderating nerve pain signals in the body. It influences immune cells and nerve cells by interacting with several receptors and pathways, including the PPAR-alpha receptor. Those actions make PEA interesting to researchers and clinicians as a potential option to relieve chronic pain and protect tissues. Because the abbreviation is easier to say, you will see PEA used often in medical studies and product labels. PEA is available as an over-the-counter supplement in many places, and many people use it hoping for fewer side effects than traditional painkillers. Clinical results are mixed depending on the condition, so it is wise to look at quality research and consult a healthcare provider before starting it. PEA's popularity highlights growing interest in treatments that work with the body's natural systems rather than simply blocking symptoms.
